Fischer Medical Ventures Limited (FMVL) has announced that its strategic partner, Nanyang Biologics, has achieved a major international milestone with its AI-powered molecular research platform, NYB.AI, being featured in the opening showcase at NVIDIA GTC Taiwan 2026, ahead of the keynote address by NVIDIA Founder and CEO Jensen Huang. The recognition places NYB.AI among a select group of innovators from NVIDIA’s global Inception ecosystem that are driving advances in artificial intelligence, computational biology and next-generation scientific research.
For Fischer Medical Ventures, this spotlight reinforces the strength of its partnership with Nanyang Biologics and aligns with the company’s vision of bringing world-class, AI-enabled molecular research capabilities to India. FMVL believes this collaboration will support India’s rapidly evolving pharmaceutical innovation ecosystem by enabling access to cutting-edge tools for discovery and development.
India is already recognised as one of the world’s leading pharmaceutical manufacturing hubs, and Fischer Medical Ventures sees the next phase of growth in advancing AI-driven drug discovery and molecular research. Through its partnership with Nanyang Biologics, the company aims to introduce advanced molecular research technologies to India, foster collaboration with pharmaceutical companies, biotechnology innovators, academic institutions and research organisations, and accelerate the discovery of novel therapeutic molecules. By combining artificial intelligence with India’s scientific expertise and rich botanical and Ayurvedic heritage, the partnership seeks to support evidence-based therapeutic innovation, subject to scientific validation and regulatory approvals.
Fischer Medical Ventures serves as the exclusive distributor in India for selected NYB technologies and scientifically developed plant-based nutraceutical products, subject to applicable regulatory requirements. In its initial phase, the collaboration focuses on introducing plant-based nutraceutical formulations designed to support cardiovascular health, liver health and overall wellness. Over time, FMVL intends to expand the partnership to include deeper collaborations with universities, pharmaceutical companies and research institutions to advance AI-enabled life sciences research in India.
Commenting on the development, Mr. Ravindran Govindan, Chairman, Fischer Medical Ventures Limited, said, “NYB.AI’s recognition at NVIDIA GTC Taiwan 2026 validates the strength of the technology developed by our strategic partner, Nanyang Biologics. We are proud to work alongside an organisation that is helping redefine AI-driven molecular research, and we look forward to introducing these capabilities to India’s scientific and pharmaceutical community.”
He added, “India possesses exceptional scientific talent, a globally respected pharmaceutical industry and a rich heritage of botanical knowledge. By combining these strengths with advanced artificial intelligence, we have an opportunity to accelerate innovation, strengthen research capabilities and contribute to the discovery of new therapies that address unmet medical needs.”
Ms. Svetlana Rao Raviwada, Whole-Time Executive Director, Fischer Medical Ventures Limited, said, “Our partnership with Nanyang Biologics is about more than bringing advanced technology to India; it is about building an AI-enabled life sciences ecosystem that strengthens collaboration between academia, research institutions and the pharmaceutical industry. Through advanced platforms such as Vecura, we aim to equip Indian researchers with world-class AI-powered molecular research capabilities that can accelerate scientific discovery and foster innovation across the healthcare and life sciences sectors.”
